AGEN

Agenus Inc.

NasdaqAdd to watchlist

Healthcare · Biotechnology

$7.85

+$0.63+8.73%

Delayed · 2026-09-18T20:00:00.000Z · marketstack

Aug 24, 2026$7.85

+$0.18+2.35%over 1M

Session

Day range95% of range

$7.33$7.88

Fundamentals

Visualize fundamentals and more

Market cap: 324.5M
P/E ratio: -

Revenue grew +10.37% in FY2025, in line with its sector. The median across Healthcare companies this platform tracks is +8.87%.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 48
dropped: 48
re-drafted: 41

Out of 346 passages in this year’s Item 1A.

New this year

• Our use of new and evolving technologies, such as artificial intelligence, or AI, may present risks and challenges that can impact our business

95 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Going concern
Labour
Russia and Ukraine
Export controls
Litigation

And 15 more.

FDA approval
Our product candidates are new molecular entities that could face challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Recent activity

23 more events are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add

Discussion

No comments yet

Set a username to join the discussion. It’s the only thing shown next to what you post, never your email address.

Comments are written by other users. Nothing here is investment advice and nothing is checked for accuracy.

Updated Sep 18, 2026 · the last close

Agenus Inc. investor relations

What AGEN has filed with the SEC. This is not Agenus Inc.’s own investor relations site: these filings are the primary source that site publishes from.

Companies like Agenus Inc.

Also filed under Biotechnology, ranked by how closely they sit beside AGEN.

MRNAModerna, Inc.compare with AGEN
ROIVRoivant Sciences Ltd.compare with AGEN
VRTXVertex Pharmaceuticals Inc. / MA

XENEXenon Pharmaceuticals Inc.compare with AGEN

NVONovo Nordisk A Scompare with AGEN

AGEN is among the largest companies matching:

gross margin above 70% and still lossmaking

Ask about Agenus Inc.

The assistant answers from what AGEN has actually filed: 17 annual reports filed with the SEC, 25 Form 4 filings from the last year and 2 funds that hold it. Every figure in a reply links to the filing it came from, so an answer can be checked rather than believed.

Press one and the answer appears right here on the page, from AGEN's filings and figures. One a day without an account; a free account has its own, and no card.

See how much of Agenus Inc. each of these investors holds, and every quarter they moved.

Ten seconds. No card. Nothing to cancel.

No card, no broker connection.

Continue with Google

What an account lets you do with Agenus Inc.

Be told the moment a AGEN insider trades
Put Agenus Inc. on a watchlist for a free alert, the bell and a daily email, when a Form 4 worth a row is filed, with vesting and automatic tax sales already struck out so what lands is a decision, not paperwork.
The full filing historyMeasure
Ask what growth the price is already betting on
Agenus Inc.'s income statement, balance sheet and cash flow as filed, and the ratios computed from them, plus a reverse DCF that holds today's price fixed and solves for the growth it requires.
The reverse DCFMeasure
Watch the same stakes the professionals are watching
Every tracked position priced at the quarter it was filed and diffed against the one before it: how big a bet each one is, and by how much it changed.
Every position, sizedMeasure
Interrogate the filing, not the internet
Ask anything about Agenus Inc.'s fundamentals. The assistant answers from its own filings and cites the figure, never a guess from the open web.

Create a free account See what the paid plans add

Free, no card, and it does not expire.

Risk factors, year on year

Item 1AMar 2026 10-KMar 2025

added: 48
dropped: 48
re-drafted: 41

Out of 346 passages in this year’s Item 1A.

New this year

• Our use of new and evolving technologies, such as artificial intelligence, or AI, may present risks and challenges that can impact our business

95 more passages are on Bespoke

Bespoke Create a free account

Free, no card, and it does not expire. See what the paid plans add

What it says it is exposed to

From Item 1A of its most recent 10-K, filed March 2026.

FDA approval
Reimbursement
Data privacy
Going concern
Labour
Russia and Ukraine
Export controls
Litigation

And 15 more.

FDA approval
Our product candidates are new molecular entities that could face challenges in obtaining regulatory approval. As a result, our ability to develop product candidates and obtain regulatory approval may be significantly impacted.

7 more themes are on Measure

Measure Create a free account

Free, no card, and it does not expire. See what the paid plans add